The problem is that most of our garri sellers in the market buy their garri from bush markets. These garri are often fried half dry and are subsequently dried on polythene sheets on the tarred roads or compounds in the villages.
Monday, January 25, 2016
Nurses and Patients flee as Lassa fever kills Two at a Federal Medical centre
While many of the patients and nurses have fled the hospital for fear of the unknown, no fewer than over 55 persons have been reportedly killed across the country in the last few weeks of its outbreak.
Health workers at FMC struggle to remove bodies of the two patients who died of Lassa Fever.
The two victims, hospital sources said died two days interval after being managed for a week plus but the State Health Commissioner, Dr. Nicholas Azinge who refused to confirm the incident, said "I know some persons have died, I cannot speak further on that because the Federal Ministry of Health is already doing something to sensitize the people and we in Delta State are also sensitising our people".
With twenty-two patients quarantined at present at the hospital, further investigation revealed that there are palpable tension and fear of the unknown among the health workers, especially the doctors who feared that the disease may be something else.
A Doctor who did not want his name in the print, said "We too we are afraid of the present situation with over twenty two persons already quarantined and so far three have died, so the situation expresses deep fears of the unknown, but by the grace of God shall overcome the situation.
Friday, December 25, 2015
Pregnancy May Explain Ebola Return
Health officials suspect recently reported cases of the disease in Liberia might stem from a flare-up of the virus in a survivor who became pregnant.
FLICKR, NIAID
Ebola infections in Liberia, which had been declared free of the virus, could have stemmed from a woman whose pregnancy caused an earlier Ebola infection to resurge, Reuters reported last week (December 17).
"Ophelia [the pregnant patient] caught Ebola more than a year ago from her brother who died of a presumed Ebola infection in July 2014," according to Reuters. "It is not known exactly how she might have transmitted the virus, which is found in bodily fluids, to her family. Despite her experiences, Ophelia is still alive."
This theory being considered by US and Liberia researchers and the World Health Organization is not yet confirmed.
Liberia was last considered Ebola-free in September, after an epidemic struck the country and region throughout 2014 and 2015, killing 4,806 in Liberia and more than 11,000 wordlwide. Butreports of infections returned in November.
The Ebola virus is known to persist in so-called immune-privileged tissues and fluids, including the placenta and amniotic fluid. These sites have less immune activity, allowing the virus to linger.
The case of Ophelia highlights the need to continue monitoring Ebola survivors for months or years, Reuters noted. "The affected countries want to say they are Ebola-free but they need help with continuing surveillance and health care monitoring," Jonathan Heeney, a professor of Comparative Pathology at Cambridge, told Reuters.
"Over time, we do think that everyone who survives Ebola will be completely Ebola-free," Daniel Bausch, an emerging pathogens expert at Tulane University, told The Scientist in November.
Microbes Play Role in Anti-Tumor Response
Gut microbiome composition can influence the effectiveness of cancer immunotherapy in mice.
WIKIMEDIA, NIH
The presence of certain types of gut microbes in mice can boost the anti-tumor effects of cancer immunotherapy, according to two studies from independent research teams published today (November 5) in Science.
Cancer immunotherapies that block immune inhibitory pathways are now available as treatments for several tumor types, yet patients' responses to these therapies vary. Aside from the presence of T cells within the tumor before the start of treatment, it has not been clear what other factors are linked to a response to these antibodies. The two studies published today, while not the first to suggest that gut microbes can influence the efficacy of cancer therapy, provide a definitive link between gut microbiome composition and cancer immunotherapy response and implicate the positive role of specific bacterial species.
"These interesting papers combine two of the hottest areas in science—the microbiome and immunology—showing that gut bacteria can activate [host] anti-tumor responses," said Timothy Hand of the department of immunology at the University of Pittsburgh who was not involved in either study.
"These are beautiful studies that give mechanistic views of how the gut microbiota is critical for regulating the immune system in the context of an immune checkpoint blockade to encourage the immune system in fighting cancer," agreed Justin Sonnenburg, a microbiome researcher at the Stanford School of Medicine who was also not involved in the research. "The microbiota is connected to our biology in both direct and indirect ways, and these works are adding to the list of how the microbiota is incredibly important for our health."
Thomas F. Gajewski, a cancer clinician and researcher at the University of Chicago, and his colleagues were interested to understand what leads some cancer patients to have a strong immune response against a tumor—in the form of T cells that infiltrate the tumor. "Differences in immune responses to cancer may be due to genetic variants, differences in the tumor mutations, environmental differences, or a combination of these factors," explained Gajewski.
To explore the role of the gut microbiome, the researchers studied two groups of the same strain of laboratory mice that had been bred at two different mouse facilities and were known to harbor different commensal bacteria in their GI tracts. When both sets of mice were implanted with melanoma tumors, tumors grew less aggressively in the mice sourced from the Jackson Laboratory (JAX) and these mice had more robust T-cells responses against the tumors. When both mouse groups were housed together, the differences in tumor responses disappeared, leading the researchers to hypothesize that commensal microbes from the JAX mice had colonized the other mouse population, sourced from Taconic Biosciences. Sure enough, a fecal transplant from the JAX mice to the other group resulted in better anti-tumor T-cell responses and slower tumor growth in the Taconic Biosciences group, even when housed separately.
Next, the researchers decided to test the effects of an anti-PD-L1 immunotherapy antibody. The therapy slowed tumor growth to a greater extent in the JAX compared to the Taconic Biosciences mice. Taconic Biosciences mice treated with the antibody had similar tumor control and immune responses to mice who'd received a fecal transplant from the JAX animals, but combining the immunotherapy and the fecal transplant led to greater tumor control.
Sequencing the gut microbiome of the mice, the researchers found that Bifidobacterium species were linked to the anti-tumor immune response and that adding a cocktail of these microbes to the Taconic Biosciences mice with melanoma resulted in the same benefit as the fecal transplant. The team also found that the dendritic cells isolated from either the JAX mice orBifidobacterium-treated Taconic Biosciences mice are able to better stimulate tumor-specific T cells in vitro.
"These effects of the gut microbiome on the anti-tumor immune response were stronger than we had anticipated," said Gajewski.
In the second study, led by immunologist Laurence Zitvogel of INSERM in France, researchers found that the effect of treating mice harboring sarcomas, melanoma, or colorectal tumors with another immunotherapy antibody, against CTLA-4, depended on the presence of Bacteroidesspecies; germ-free or antibiotics-treated mice did not enjoy tumor control as a result of the therapy. Adding Bacteroides species to the germ-free and antibiotics treated mice restored the immunotherapy's anti-tumor benefit. Interestingly, adding murine memory T cells targeting the gut microbes to the mice had the same effect, suggesting that it is the immune system's response to commensal microbes that readies it to fight tumors.
Analyzing gut microbiome of 25 metastatic melanoma patients, the INSERM researchers also found that some patients had Bacterioides as part of their gut microbiomes and that a fecal transplant from these patients into germ free mice also restored the anti-CTLA-4 therapy's anti-tumor effects.
"What was quite exciting for us is that using microbes may be a way to improve the efficacy of immunotherapies without increasing their toxic side effects," said study author Mathias Chamaillard, an immunologist at the Center of Infection and Immunity at the University of Lille in France. Both groups of researchers are now sorting out the details of how the gut microbes stimulate the immune system to act against tumors.
Of course, whether the gut microbial species identified in these mouse studies will have the same effect in people is not clear. "The impact of the gut microbiota is probably different depending on the context," said Gajewski. "We're starting to understand that that one type of bacteria is not going to cure everything."
M. Vétizou et al., "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota,"Science, doi:10.1126/aad1329, 2015.
A. Sivan et al., "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy," Science, doi:0.1126/science.aac4255, 2015.
Correction (November 6): This story has been updated from its original version to correctly name the origin of some of the study animals as Taconic Biosciences, not Taconic Farms. The Scientist regrets the error.
MERS Vax Tested in Camels
Scientists conduct the first MERS-CoV vaccine trials in camels and provide viral lineage evidence of camel-to-human transfer.
Immunization of dromedary camels with a novel vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV) resulted in an immune response in the animals and reduced infection following a MERS challenge. The study, the first to analyze the effect of a MERS-CoV vaccine on viral load in camels, is published today (December 17) in Science.
"This study is an important step forward in the research and development of countermeasures for MERS-CoV," Kayvon Modjarrad, an infectious disease specialist at the Walter Reed Army Institute of Research in Bethesda, Maryland, who was not involved in the study, wrote in an email to The Scientist.
Virologist Bart Haagmans of the Erasmus Medical Center, in Rotterdam, the Netherlands, and his colleagues tested the efficacy of a MERS vaccine consisting of a modified vaccinia virus Ankara (MVA) vector in an eight-camel pilot study. The vaccine virus expresses the MERS-CoV spike protein, which is found in other MERS vaccines being tested.
The researchers inoculated four dromedary camels with the vaccine and four animals with a control MVA vaccine virus, by injection (in the neck) and delivering the vaccine to the animals' airways using an atomizer. The vaccinated animals developed detectable serum neutralizing MERS-CoV antibodies against the spike protein within three weeks, the researchers reported.
The scientists then challenged the camels with high doses of MERS-CoV into their nostrils. The levels of MERS-CoV in the vaccinated animals were significantly lower compared to that in the control animals. One of the four vaccinated camels excreted infectious virus particles six days after infection, yet sequencing of the spike gene of these particles showed that they coded for the same spike protein sequence, indicating that the virus had not mutated after encountering anti-S protein antibodies.
"Not only do we show [the vaccine] is immunogenic and has protective efficacy, but using MVA as a vector has the advantage of inducing immunity also to a different, camelpox virus," Haarmans said.
David Weiner, a professor of pathology at the University of Pennsylvania whose laboratory is working on the synthetic MERS vaccine but was not involved in the current study, noted that adult camels infected with camelpox inoculated with the MVA-based vaccine may develop resistance to the vaccine. "The simultaneous camel pox immunity may be a double-edged sword," he said.
What is not yet clear is how quickly MERS-CoV mutates, and whether one vaccine results in persistent immunity or if multiple immunizations may be required, said Trish Perl, an epidemiologist at Johns Hopkins University in Baltimore who was not involved with the work.
Because little is known about the adaptive immune systems of dromedary camels, new tools are needed to measure T cell and antibody responses for future, longer studies of the vaccine, said Haagman. It will also be important to compare the results of this vaccine with the several others vaccine candidates being tested, Modjarrad noted.
Toward understanding how MERS-CoV may evolve in the camel, a confirmed animal reservoir of the virus, researchers at the University of Hong Kong and their colleagues, isolated and sequenced MERS-CoV strains from dromedary camels, identifying five lineages including a recombinant one implicated in human outbreaks in 2015. Their analysis, one of the first to provide direct evidence of camel-to-human MERS-CoV transmission, also appeared today (December 17) in Science.
Yi Guan, director of the State Key Laboratory of Emerging Infectious Diseases at the University of Hong Kong, and his colleagues isolated nasal samples from 1,309 dromedary camels in Saudi Arabia. Along with MERS-CoV, the researchers found that the human 229E-like coronavirus was also prevalent within some of the infected camels.
"Our study is the first to provide a detailed picture of the evolution of the virus in its direct host, showing clearly the development of the virus in camels and its transmission to humans," Guan wrote in an email to The Scientist.
It's not yet clear how MERS-CoV is transmitted from camels to people. "We now have the animal side of the story," said Perl, "but now we need to look at the human side of the story."
"The state of the science on this emerging pathogen is still relatively young and there is much to learn about MERS-CoV biology, pathogenesis, and epidemiology," Modjarrad wrote.
B.L. Haagmans et al., "An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels," Science, doi:10.1126/science.aad1283, 2015.
J.S.M Sabir et al., "Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia," Science, doi:10.1126/science.aac8608, 2015.
Monday, November 30, 2015
Several Job Vacancies at The Institute of Human Virology (IHVN)
The Institute of Human Virology (IHVN) is a leading and reputable indigenous non-governmental organization implementing comprehensive HIV/AIDS prevention, care and treatment, Multi-Drug Resistant TB, Malaria and Research Programs, in partnership with the different tiers of the Government of Nigeria, health facilities and community-based organizations.
The organization is seeking applications from suitable qualified candidates to occupy the position below:
Senior Program Officer Maternal,
Neonatal and Child Health (MNCH)
Laboratory TB Consultant
Program Officer Maternal, Neonatal and Child Health (MNCH)
Program Manager, Prevention and Community DR-TB
Senior Program Officer Care and Support (C&S)
Program Officer Care and Support (C&S)
Monday, August 3, 2015
How bees naturally vaccinate their babies
choice—they naturally immunize their offspring against specific
diseases found in their environments. And now for the first time, scientists have discovered how they do it.
Researchers from Arizona State University, University of
Helsinki, University of Jyväskylä and Norwegian University of Life Sciences made the discovery after studying a bee blood protein called vitellogenin. The scientists found that this protein plays a critical, but previously unknown role in providing bee babies protection against disease.
The findings appear today in the journal PLOS Pathogens. "The process by which bees transfer immunity to their babies was a big mystery until now. What we found is that it's as simple as eating," said Gro Amdam, a professor with ASU's School of Life Sciences and co-author of the paper. "Our amazing discovery was made possible because of 15 years of basic research on vitellogenin. This exemplifies how long-term
investments in basic research pay off."
Co-author Dalial Freitak, a postdoctoral researcher with
University of Helsinki adds: "I have been working on bee immune priming since the start of my doctoral studies. Now almost 10 years later, I feel like I've solved an important part of the puzzle. It's a wonderful and very rewarding feeling!"
How it works
In a honey bee colony, the queen rarely leaves the nest, so
worker bees must bring food to her. Forager bees can pick up
pathogens in the environment while gathering pollen and nectar.
Back in the hive, worker bees use this same pollen to create
"royal jelly"—a food made just for the queen that incidentally
contains bacteria from the outside environment.
After eating these bacteria, the pathogens are digested in the gut and transferred to the body cavity; there they are stored in the queen's 'fat body'—an organ similar to a liver. Pieces of the bacteria are then bound to vitellogenin—a protein—and carried via blood to the developing eggs. Because of this, bee babies are 'vaccinated' and their immune systems better prepared to fight
diseases found in their environment once they are born.
Vitellogenin is the carrier of these immune-priming signals,
something researchers did not know until now.
First edible vaccines for bees
While bees vaccinate their babies against some diseases, many pathogens are deadly and the insects are unable to fight them.
But now that Amdam and Freitak understand how bees vaccinate their babies, this opens the door to creating the first
edible and natural vaccine for insects.
"We are patenting a way to produce a harmless vaccine, as well as how to cultivate the vaccines and introduce them to bee hives through a cocktail the bees would eat. They would then be able to stave off disease," said Freitak.
One destructive disease that affects bees is American Foul
Brood, which spreads quickly and destroys hives. The bacterium infects bee larvae as they ingest food contaminated with its spores. These spores get their nourishment from the
larvae, eventually killing them.
This disease is just one example where the researchers say a
vaccine would be extremely beneficial.
Why this discovery is important to humans
It's widely known that pollinators, including bees, are facing serious environmental dangers. During the past six decades, managed honey bee colonies in the United States have declined from 6 million in 1947 to only 2.5 million today. Not only are bees affected by diseases, they have been decimated by a phenomenon called colony collapse disorder.
Researchers don't know exactly what causes this, but pesticides, pests, pathogens and nutrition problems may all be
contributing factors.
According to a 2014 report by the U.S. government, pollinators
are instrumental for a healthy economy and critical to food
security, contributing 35 percent of global food production. In North America, insects pollinate 87 of the top 115 food crops and honey bees are vital in keeping fruits, nuts and vegetables in our diets.
Humans depend on bees and other pollinating insects for a huge
portion of their food supply. Insect vaccines could play an
important role in helping to combat colony collapse disorder, in addition to fighting a variety of diseases.
All egg-laying species have vitellogenin
This discovery could have far-reaching benefits for other
species, as well as substantial, positive impacts on food
production. All egg-laying species including fish, poultry,
reptiles, amphibians and insects have vitellogenin in their
bodies.
The food industry could implement the use of natural vaccines that would not only be inexpensive to produce, they could easily be used in developing countries.
"Because this vaccination process is naturally occurring, this process would be cheap and ultimately simple to implement. It has the potential to both improve and secure food production for humans," said Amdam.
First ever successful field testing of Ebola vaccine reported
Guinea, West Africa - called rVSV-ZEBOV - has revealed that it is effective in protecting individuals and containing the spread of the deadly virus.
The World Health Organization (WHO) trial, whose results are
published in both The Lancet and The BMJ, was designed by
researchers from the University of Bern in Switzerland.
A technique known as "ring vaccination" was the inspiration
for the trial. This method involves tracking down and
vaccinating anyone who may have been exposed to someone
carrying a virus, in order to contain its spread. Ring vaccination was behind the eradication of smallpox in the 1970s.
For the trial, researchers first identified people who, within the previous 21 days, had been in close contact with someone that had recently contracted the Ebola virus. These people were
considered to be directly at risk and included relatives,
household members and clinical staff.
Next, they identified people who might have been indirectly at
risk of contracting the virus. These included the neighbors and
work colleagues of people identified in the first step of the trial.
Together, all of these people were considered to be part of a
"ring," and if they were considered eligible to receive the rVSV-ZEBOV vaccine, they were asked to participate in the
trial.
A total of 90 rings were identified for examination by the researchers, consisting of 5,415 contacts who were eligible for vaccination. Of these, a total of 3,512 individuals were
recruited and received the vaccination.
Participating rings were then randomly assigned into one of
two equally sized groups. One group received the Ebola vaccine immediately, while the other group was vaccinated after 21 days - the incubation period of the virus.
Although this approach meant that some participants would
likely contract Ebola, study author Dr. Matthias Egger states
that it was the only way they could test whether the vaccine
really worked.
Could this be the end of the Ebola epidemic in West Africa?
The researchers found that none of the people who were
vaccinated immediately contracted Ebola, compared with 16 cases of Ebola reported in the group whose vaccination was
delayed. Each of these 16 cases developed within 6 days of the
vaccination being administered. After this time, no further cases were reported.
Dr. Sven Trelle, from the Clinical Trials Unit at Bern
University Hospital, states that these findings indicate the
vaccine offers full protection from Ebola after around 1 week.
Fast facts about Ebola
• The 2014 Ebola outbreak is the worst outbreak ever recorded
• Ebola has a fatality rate of up to 90%
• The virus is characterized by abrupt onset of fever, weakness and headache.
Looking at the rings overall - which contained several
individuals who had not received the vaccination - the
researchers observed that a 76% level of protection had been afforded, suggesting that implementing the vaccine had a broadly disruptive effect on virus transmission.
"It is not just the efficacy of the Ebola vaccine that has now
been shown but also the effectiveness of the ring vaccination strategy," explains Dr. Egger. "This could finally be the beginning of the end of the Ebola epidemic in West Africa and also be useful when combating this disease in the future."
Following the success of the initial trial, a data and safety
monitoring board advised that the trial be expanded to gain
further evidence on the vaccine's effectiveness. The board suggested stopping the randomization, however, and simply vaccinating new clusters of eligible participants.
"The continued enrollment, immediate vaccination, and follow-up of clusters will generate additional data about the effectiveness of ring vaccination to protect communities through herd immunity, and will hopefully help to stop Ebola virus disease transmission in Guinea," the authors conclude.
While Guinea has been one of the countries most affected by the Ebola epidemic, a recent report published in The Lancet
Infectious Diseases suggests that rising numbers of malaria
deaths have greatly exceeded the total number caused by Ebola, possibly due to the manner in which Ebola disrupted the country's health care facilities.




